Skip to main content
PolicySpeak
← All files
MLH

Mölnlycke Health Care AB

Company · Sweden · EU Transparency Register 150331249562-81

3
positions filed
in the 326 files tracked
1
legislative file
of 326 tracked
3
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 925 companies & groups on this site, they rank #528 by legislative files engaged — a count of participation, not a measure of influence.

1
declared lobbying FTE
self-declared
€300K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2023
in the register since

Declares membership of

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).

Register category
Companies & groups
Head office
Mölndal, Sweden

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track Mölnlycke in PolicySpeak: request access →

Work at Mölnlycke Health Care AB? so we know who speaks for it.

Follow the file Mölnlycke Health Care AB engages with

One email on Tuesdays when a new position is filed on this file, from Mölnlycke Health Care AB or from anyone else on it. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

Mölnlycke Health Care AB filed 3 positions between 6 Oct 2025 and 7 Jul 2026, across 1 of the 326 legislative files tracked here, attaching a full position paper 3 times.

2025 · 1 filed2026 · 2 filed

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 7 Jul 2026PDFsource

Mölnlycke welcomes the proposed revision to the Medical Device Regulation (MDR), as it represents an important step toward improving regulatory efficiency. The company supports the need to accelerate the application of these changes and avoid extending implementation timelines to three to five years.

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 16 Jun 2026PDFsource

As leading Medtech companies in Europe, Ambu, Coloplast, Mölnlycke, and Solventum support the response submitted by Swedish Medtech to the Commissions consultation on the revision of the MDR, and are hereby submitting our joint statement to further highlight key issues and recommendations.

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 6 Oct 2025PDFsource

Mölnlycke is eager to share insights based on its MDR early-adopter experience to inform the forthcoming revision of the Regulation. While the current Medical Device Regulation (EU) 2017/745 is a significant step towards creating uniform legislation for all actors in the medical device sector, there are areas where the European Commission can improve clarity and oversight to ensure the availability of…

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Is this your organization?

Everything on this page comes from Mölnlycke Health Care AB’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.